PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-26.45%
Negative revenue growth while MCHP stands at 3.10%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-33.23%
Negative gross profit growth while MCHP is at 3.65%. Joel Greenblatt would examine cost competitiveness or demand decline.
-87.40%
Negative EBIT growth while MCHP is at 36.92%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-93.30%
Negative operating income growth while MCHP is at 3.14%. Joel Greenblatt would press for urgent turnaround measures.
-80.99%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-79.07%
Negative EPS growth while MCHP is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-79.07%
Negative diluted EPS growth while MCHP is at 5.26%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.76%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-2.28%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
9.57%
Maintaining or increasing dividends while MCHP cut them. John Neff might see a strong edge in shareholder returns.
6.27%
Positive OCF growth while MCHP is negative. John Neff would see this as a clear operational advantage vs. the competitor.
21.75%
Positive FCF growth while MCHP is negative. John Neff would see a strong competitive edge in net cash generation.
121.43%
10Y revenue/share CAGR at 75-90% of MCHP's 157.37%. Bill Ackman would press for new markets or product lines to narrow the gap.
81.93%
5Y revenue/share CAGR similar to MCHP's 83.72%. Walter Schloss might see both companies benefiting from the same mid-term trends.
-13.17%
Negative 3Y CAGR while MCHP stands at 35.84%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
367.14%
10Y OCF/share CAGR at 50-75% of MCHP's 612.67%. Martin Whitman might fear a structural deficiency in operational efficiency.
111.98%
5Y OCF/share CAGR above 1.5x MCHP's 63.78%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
54.17%
3Y OCF/share CAGR at 75-90% of MCHP's 65.24%. Bill Ackman would press for improvements in margin or overhead to catch up.
0.30%
Below 50% of MCHP's 395.62%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-57.80%
Negative 5Y net income/share CAGR while MCHP is 325.06%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-79.55%
Negative 3Y CAGR while MCHP is 47.51%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
153.14%
10Y equity/share CAGR in line with MCHP's 159.51%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
59.03%
Positive 5Y equity/share CAGR while MCHP is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-2.17%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
656.97%
Dividend/share CAGR of 656.97% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
692.36%
Below 50% of MCHP's 1480.47%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
267.82%
3Y dividend/share CAGR at 75-90% of MCHP's 351.70%. Bill Ackman wants overhead or revenue enhancements to match competitor's dividend growth.
-48.53%
Firm’s AR is declining while MCHP shows 20.91%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-12.70%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-4.36%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-5.95%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-14.99%
Our R&D shrinks while MCHP invests at 3.96%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-7.18%
We cut SG&A while MCHP invests at 4.36%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.